TL;DR
It is demonstrated that NAC1 may be a critical factor in the development of chemoresistance, offering a potential novel target for the treatment of CRC.
: Objectives: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, largely due to the emergence of resistance to standard chemotherapeutic regimens. The identification of molecular determinants of chemoresistance is therefore critical to improve patient stratification and therapeutic efficacy. H...
PON2 appears to sustain chemoresistance by affecting important mechanisms related to ROS detoxification, glucose metabolism, and anti-apoptotic signaling by affecting important mechanisms related to ROS detoxification, glucose metabolism, and anti-apoptotic signaling.
It is demonstrated that FAL1 drives cisplatin resistance in LUAD by shifting the balance between apoptosis and autophagy through the BMI1/BIM axis.
identifies IDO1 as a key regulator of oxidative stress-associated, caspase-dependent apoptosis in gastric cancer and suggests that targeting IDO1 in combination with platinum-based chemotherapy represents a promising strategy to enhance the efficacy of gastric cancer treatment.
This study revealed that cisplatin could promote ecDNA generation, which enhanced malignant phenotypes, including cell proliferation, motility and drug resistance, and was associated with poorer patient prognosis, and targeting ecDNA with inhibitors could reverse these effects.
The study demonstrates that TFEB regulates the expression of the multidrug efflux transporter ATP-binding cassette subfamily G member 2 (ABCG2), a crucial factor in drug resistance mechanisms, and targets TNKS represents a potentially effective therapeutic approach to address cisplatin resistance and improve treatment...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
